News >

Strickler Stresses Continued Focus on Molecular Subtypes in mCRC

Brandon Scalea
Published: Friday, Mar 08, 2019

John Strickler, MD

John Strickler, MD
Effective therapies are being tailored to small subsets of patients with certain molecular abnormalities in their tumors, but the next steps for research in metastatic colorectal cancer (mCRC) are to turn these incremental benefits into long-term survival, said John Strickler, MD.

As treatment options become more widespread in this space, there is also a greater focus on quality of life. In the phase II ReDOS trial, investigators evaluated a dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg daily for patients with mCRC. Regorafenib is an active TKI, but it can come with significant toxicities, such as hand-foot syndrome and fatigue.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x